Despite a 2018 American Academy of Pediatrics (AAP) clinical update which recommends use of post-exposure prophylaxis (PEP) for prevention of the tick-borne disease in kids younger than 8 years of age, Wesley Kufel, PharmD, BCPS, BCIDP, FCCP, FIDSA, points out many clinicians are unaware of this. He also discusses its efficacy at preventing the disease in this patient population.
Results from a new survey taken this past summer show immunization confidence waning among the public and some factual uncertainty around immunization. In this time of disinformation and misinformation, Ruth Lynfield, MD, discusses an approach clinicians can take in counseling parents who may have concerns about the vaccine as well as other strategies to increase immunization adherence.
In his new position, Gareth Morgan, MS, MBA, provides insights on antibiotic development strategies he would like to see during his tenure.
Jill Blumenthal, MD, MAS, offers some insights on the results from a subset of Gilead’s phase 3 PURPOSE 2 study.
Ashlan Kunz Coyne, PharmD, MPH, discusses the potential of combining antibiotics with phage mixture therapy in treating these types of infections.
George Sakoulas, MD, discusses how transitioning pneumonia patients from IV to oral therapy after 3 to 4 days of clinical stability supports effective 7-day treatment courses, while patients who are immunocompromised and those with Pseudomonas infections require individualized, extended management.
Jesse Clark, MD, MSc, discusses a study’s subset preliminary findings looking at this form of PrEP in this patient population.
Dumkow discusses her goals for her tenure as well as professional societies' roles in public health advocacy and AI.
George Sakoulas, MD, discusses how updated guidelines recommend shorter antibiotic courses (5 to 7 days) for patients with pneumonia, emphasizing that early aggressive treatment within the first 72 hours is crucial for reducing hospital stays and improving patient outcomes.
George Sakoulas, MD, discusses how ceftaroline serves as an effective stewardship-aligned option for community-acquired pneumonia involving gram-positive organisms, particularly in older and high-risk patients, while noting its limitations in gram-negative and health care–associated infections.
The Center for Discovery and Innovation’s chief scientific officer David Perlin, PhD, discusses the factors for the growing number of cases and the difficulties in developing such treatments.
The center’s chief scientific officer David Perlin, PhD, provides some insights on the evolution of its antiviral program from its foundation in treating COVID-19 to addressing all pan-coronaviruses.
George Sakoulas, MD, discusses how antimicrobial selection for patients with pneumonia depends on illness severity, seasonal pathogen patterns, comorbidities, and prior antibiotic exposure, with particular attention to high-risk populations requiring tailored therapy.
George Sakoulas, MD, discusses how COVID-19 has disrupted traditional respiratory virus patterns with summer surges now preceding the typical winter influenza season, while declining vaccine uptake among younger populations threatens to leave vulnerable groups increasingly exposed to seasonal illness complications.
William Schaffner, MD, reviews clinical workup, treatment, and preventative measurements.
Panelists discuss the urgent need to ensure equitable access to novel antibiotics, highlighting global and domestic disparities, the vital role of stewardship programs, and the importance of innovative distribution models, international collaboration, and systemic reforms to bring lifesaving treatments to resource-limited settings.
Panelists discuss the complex, systemwide stewardship considerations for incorporating new antibiotics targeting resistant pathogens, emphasizing the need for real-world efficacy data, thoughtful formulary restrictions, and tailored strategies for outpatient use to ensure safe, effective, and sustainable adoption across diverse care settings.
Panelists discuss how regulatory incentives are advancing antimicrobial development, enabling a shift away from older, toxic agents like colistin, while acknowledging that despite the superiority of newer therapies, polymyxins still retain a limited role in rare, highly resistant infections where no better alternatives exist.
Panelists discuss how the clinical use of new antibiotics often extends beyond US Food and Drug Administration (FDA)–approved indications, driven by microbiological activity and clinical judgment, while highlighting the role of regulatory incentives like Qualified Infectious Disease Product (QIDP) in accelerating drug development and the need for careful, collaborative interpretation of limited trial data to ensure responsible off-label use.
Panelists discuss the challenges of implementing susceptibility testing for new antibiotics, emphasizing the need for close lab-clinician collaboration, streamlined reflex testing protocols, and investment in diagnostic infrastructure to ensure timely and effective treatment of multidrug-resistant infections.
Panelists discuss the evolving landscape of novel antibiotic combinations targeting metallo-β-lactamase (MBL)–producing and other multidrug-resistant Gram-negative bacteria, emphasizing promising early data despite limited clinical trials, the complexity of resistance mechanisms, and the potential for these therapies to improve outcomes and shape future treatment strategies.
Panelists discuss the innovative use of the aztreonam-avibactam combination to combat complex β-lactamase–mediated resistance, highlighting promising laboratory data, challenges in clinical trial enrollment for resistant infections, and the ongoing need for further research to define its role in treating multidrug-resistant Gram-negative pathogens.
Panelists discuss the real-world challenges of managing infections caused by highly resistant organisms, highlighting the impact of limited access to novel diagnostics and therapeutics, the complexities of outpatient treatment, and the urgent need for broader-spectrum agents and improved delivery methods in resource-constrained settings.
Jennifer Le, PharmD, MAS, FIDSA, FCCP, FCSHP, discusses her collaboration on this innovative work with this therapy in severely ill children.
